Biotech company kills resistant bacteria using Crispr – bets on beating market crisis
Snipr Biome is developing a new type of antibiotic, which kills bacteria using the gene-editing tool Crispr. The company plans to cut through the financial crisis on the antibiotic market by, for example, directing the treatment towards cancer patients.
BY KEVIN GRØNNEMANN, TRANSLATED BY NIELSINE NIELSEN
A small Copenhagen-based biotech firm has great ambitions to combat resistant bacteria – and a plan for how to succeed in spite of the financial crisis plaguing the antibiotics market.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
